Streetbeat News

TEM

Tempus AI Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

76.51

Mkt cap

10B

Volume

15M

High

77.00

P/E Ratio

-13.20

52-wk high

91.45

Low

67.74

Div yield

N/A

52-wk low

22.89

Tempus AI is making strategic moves in the AI-driven healthcare sector, including acquiring Ambry Genetics, launching the Olivia health app, and collaborating with IFLI. These initiatives, along with their innovative assets, position them well for growth in precision diagnostics and personalized treatments.

Portfolio Pulse from

February 18, 2025 | 2:15 pm

Tempus AI, a leader in precision medicine and AI, has seen its stock price increase by over 160% in the last month and nearly 150% year-to-date, sparking significant investor interest.

Portfolio Pulse from

February 17, 2025 | 1:45 pm

Tempus AI stock has surged nearly 99% since the start of the year, driven by its innovative AI solutions in healthcare. Despite the strong performance, there may still be growth potential for the stock.

Portfolio Pulse from

February 13, 2025 | 11:45 am

Tempus AI (TEM) has achieved an 82% YTD return, outperforming the market and AI stocks. The recent acquisition of Ambry Genetics is seen as positive. Preliminary Q4 and FY earnings were as expected.

Portfolio Pulse from

February 05, 2025 | 3:00 pm

Tempus AI has launched an AI-enabled personal health concierge app called olivia, which is expected to boost revenues for its AI applications business. The company sees significant potential in the oncology market and other testing areas.

Portfolio Pulse from

January 28, 2025 | 11:45 am

Tempus AI's Genomics unit is anticipated to show strong growth in the upcoming Q4 earnings report, driven by continued unit growth.

Portfolio Pulse from

January 27, 2025 | 5:30 pm

Tempus AI (NASDAQ: TEM) stock surged 45% in a week following the launch of its AI app, Olivia. Despite being listed in June 2024 and losing 16% of its value last year, the recent product launch has positively impacted its stock price.

Portfolio Pulse from

January 27, 2025 | 3:30 pm

Tempus AI is considered a high-risk buy due to its advanced AI-enabled diagnostic platform, despite facing challenges in US healthcare reimbursement. The company collaborates with over 2,500 institutions to gather real-time clinical data on cancer patients, improving treatment matching and clinical research. Its main products include Genomics, Data, and Applications, which provide diagnostic tests, data licensing, and AI-driven patient-provider connections for clinical trials.

Portfolio Pulse from

January 23, 2025 | 8:30 pm

Tempus AI has launched 'olivia', an AI-powered health concierge app aimed at transforming patient care and engagement across the country. This development has positively impacted TEM stock.

Portfolio Pulse from

January 23, 2025 | 5:15 pm

Tempus AI (TEM) stock has surged 40% in January. The article discusses reasons behind the rise and evaluates if it's still a good investment opportunity.

Portfolio Pulse from

January 23, 2025 | 3:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.